Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 383 clinical trials
featured
PHASE III RANDOMIZED, PLACEBO-CONTROLLED CLINICAL TRIAL EVALUATING THE USE OF ADJUVANT ENDOCRINE THERAPY +/- ONE YEAR OF EVEROLIMUS IN PATIENTS WITH HIGH-RISK, HORMONE RECEPTOR-POSITIVE AND HER2/NEU NEGATIVE BREAST CANCER.

PHASE III RANDOMIZED, PLACEBO-CONTROLLED CLINICAL TRIAL EVALUATING THE USE OF ADJUVANT ENDOCRINE THERAPY +/- ONE YEAR OF EVEROLIMUS IN PATIENTS WITH HIGH-RISK, HORMONE RECEPTOR-POSITIVE AND HER2/NEU NEGATIVE BREAST CANCER.

hormone therapy
HER2
endocrine therapy
breast cancer
erbb2
  • 220 views
  • 24 Nov, 2020
  • 1 location
MEN1611 With Trastuzumab (+/- Fulvestrant) in Metastatic Breast Cancer

The main purpose of this open-label, dose-escalation, phase Ib study is to identify the appropriate dose of MEN1611 to be used in combination with Trastuzumab with/without Fulvestrant for the treatment of advanced or metastatic HER2-positive breast cancer

  • 5 views
  • 25 May, 2021
  • 34 locations
Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low Hormone Receptor Positive Metastatic Breast Cancer

This study will evaluate the efficacy, safety and tolerability of trastuzumab deruxtecan compared with investigator's choice chemotherapy in human epidermal growth factor receptor (HER)2-low, hormone receptor (HR) positive breast cancer patients whose disease has progressed on endocrine therapy in the metastatic setting.

  • 37 views
  • 19 Sep, 2021
  • 278 locations
Breast Cancer Toxicity

The aims of the cohort will be to quantify impact of cancer treatments toxicities , and to generate predictors of chronic toxicity in patients with non-metastatic breast cancer. The

  • 0 views
  • 18 Mar, 2021
  • 1 location
Capivasertib + Palbociclib + Fulvestrant for HR+/HER2- Advanced Breast Cancer (CAPItello-292).

Receptor 2-Negative Locally Advanced, Unresectable or Metastatic Breast Cancer (CAPItello-292).

  • 0 views
  • 09 Sep, 2021
  • 18 locations
Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer

Phase III, double-blind, randomised study assessing the efficacy of capivasertib + fulvestrant vs placebo + fulvestrant for the treatment of patients with locally advanced (inoperable) or metastatic HR+/HER2- breast cancer following recurrence or progression on or after AI therapy.

  • 52 views
  • 20 Sep, 2021
  • 225 locations
Functional Precision Oncology for Metastatic Breast Cancer

This is a pilot study to assess the feasibility of comprehensive genomic characterization and drug screening in metastatic breast cancer. The trial will seek to provide personalized genomic and

  • 0 views
  • 19 Apr, 2021
  • 1 location
Exercise Treatment With Standard Therapy for Metastatic Breast Cancer

This study will test any good and bad effects of aerobic exercise performed while you are receiving the usual first-line treatment for metastatic breast cancer. The researchers think that

  • 3 views
  • 19 May, 2021
  • 8 locations
Everolimus (RAD001) and Carboplatin in Pretreated Metastatic Breast Cancer

taxane- and anthracycline-pretreated patients with progressive metastatic breast cancer. Additionally, the study is designed to characterize the safety, the tolerability and efficacy of this

taxane
stage iv breast cancer
anthracyclines
carboplatin
  • 22 views
  • 07 Nov, 2020
  • 1 location
Docetaxel and Ifosfamide in Treating Women With Metastatic Breast Cancer

and ifosfamide in treating women who have metastatic breast cancer.

stage iv breast cancer
tumor cells
docetaxel
  • 37 views
  • 07 Nov, 2020
  • 5 locations